Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oyster Point Pharma Inc.

https://oysterpointrx.com/

Latest From Oyster Point Pharma Inc.

TopiVert Seeks Slot In Dry Eye Disease

The London-based group has begun a Phase IIb/III study evaluating TOP1630 which has a safety and tolerability profile that could prove superior to current treatments such as Allergan's market leader Restasis.

Ophthalmic Clinical Trials

Venture Funding Deals: Spin-Outs From Axovant, Inovio & Sosei

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced January and February 2019.

Deals Financing
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Oyster Point Pharma Inc.
  • Senior Management
  • Jeffrey Nau, PhD, Pres. & CEO
    Mark Murray, CFO
    Dawn Pruitt Koffler, VP, Mktg.
  • Contact Info
  • Oyster Point Pharma Inc.
    Phone: (609) 382-9032
    700 Alexander Park Dr., Ste. 301
    Princeton, 08540
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register